AbCellera Biologics Inc.
ABCL
Classement en actions
#4229
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Prix de l'action
$11.66
Capitalisation boursière
$3.78B
Changement (1 jour)
-2.26%
Changement (1 an)
98.99%
Pays
CA
Échange AbCellera Biologics Inc. (ABCL)
Catégorie
Healthcare
Ratio P/B pour AbCellera Biologics Inc. (ABCL)
Ratio P/B au October 2026 TTM : 4.22
Selon les derniers rapports financiers et le cours de l'action de AbCellera Biologics Inc., le ratio cours/valeur comptable actuel (TTM) est 4.22. À la fin de 2023, le ratio P/B était de 1.43.
Historique du ratio P/B pour AbCellera Biologics Inc. de 2018 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 4.22 | 414.44% |
| 2024 | 0.82 | -43.01% |
| 2023 | 1.43 | -38.80% |
| 2022 | 2.34 | -39.10% |
| 2021 | 3.84 | -70.56% |
| 2020 | 13.06 | -98.53% |
| 2019 | 885.28 | 15.51% |
| 2018 | 766.43 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | 48.18% |
US
|
|
| 13.2547 | 214.21% |
US
|
|
| 4.208 | -0.25% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 46.56% |
NL
|
